| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033772731 |
| P356 | DOI | 10.1038/SJ.LEU.2400921 |
| P698 | PubMed publication ID | 9529123 |
| P5875 | ResearchGate publication ID | 51321581 |
| P2093 | author name string | D Birnbaum | |
| O Rosnet | |||
| S Marchetto | |||
| C Lavagna-Sévenier | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | 301-310 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates | |
| P478 | volume | 12 |
| Q55068988 | A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation. |
| Q37724957 | Bench to bedside targeting of FLT3 in acute leukemia |
| Q34405560 | Beyond the RING: CBL proteins as multivalent adapters |
| Q54329349 | CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors. |
| Q33647411 | Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias |
| Q53405286 | Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. |
| Q24303657 | Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation |
| Q33702150 | Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML |
| Q36368800 | Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling |
| Q38943129 | Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability |
| Q38721796 | FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors |
| Q39513601 | FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations |
| Q37810061 | FLT3 inhibitors in acute myeloid leukemia |
| Q40081796 | FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells |
| Q35127958 | FLT3/ITD AML and the law of unintended consequences |
| Q40485872 | FLT3/ITD mutation signaling includes suppression of SHP-1. |
| Q35217399 | FLT3: ITDoes matter in leukemia |
| Q28505818 | Fiz1, a novel zinc finger protein interacting with the receptor tyrosine kinase Flt3 |
| Q35625631 | Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications |
| Q36318153 | Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia |
| Q33737486 | Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). |
| Q34595162 | Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status |
| Q38166527 | Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies |
| Q34591403 | Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens |
| Q34133267 | Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease |
| Q40792187 | Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor |
| Q47716589 | Inhibition of USP10 induces degradation of oncogenic FLT3. |
| Q27824787 | Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor |
| Q35909275 | Kinase inhibitors in leukemia |
| Q37294768 | Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors |
| Q35594041 | Novel FLT3 tyrosine kinase inhibitors |
| Q40218888 | Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways |
| Q38720331 | RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia. |
| Q35849949 | Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. |
| Q42229089 | Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment. |
| Q36251180 | Signal transduction of oncogenic Flt3. |
| Q24338964 | Structural and functional alterations of FLT3 in acute myeloid leukemia |
| Q73501441 | Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines |
| Q34229555 | The Biology and Targeting of FLT3 in Pediatric Leukemia |
| Q28272735 | The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells |
| Q33838356 | The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis |
| Q24319174 | The role of FLT3 in haematopoietic malignancies |
| Q34117785 | Transcriptome dynamics during human erythroid differentiation and development |
| Q34636735 | Treatment of FLT3-ITD acute myeloid leukemia. |
| Q33767026 | Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia |
| Q34658532 | Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease |
| Q54546714 | Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. |
Search more.